{"entity":{"id":"nct06228326","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Docetaxel in metastatic cancer, run by Krystal Biotech, Inc., now recruiting.","summary":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs is a phase 1/2 interventional study registered as NCT06228326 by Krystal Biotech, Inc., with 250 participants planned, started 2024-04-17 and due to reach its primary completion in 2027-02. Interventions recorded: KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel. Conditions listed: Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06228326","url":"https://clinicaltrials.gov/study/NCT06228326"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","docetaxel"],"companies":["krystal-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06228326","phase":"1/2","setting":"KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs","sponsor":"Krystal Biotech, Inc.","enrolled":250,"outcomes":[]},"route":"/trials/nct06228326/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"krystal-biotech","kind":"company","name":"Krystal Biotech","route":"/companies/krystal-biotech/"}]}}